MR-guided adaptive versus CT-guided stereotactic radiotherapy for prostate cancer: Where is the best cost-benefit balance?

Authors :: A. Castelluccia
D. Marchesano
G. Grimaldi
I. Annessi
F. Bianciardi
A. Di Palma
M. Valentino
L. Verna
V. Confaloni
F. Rea
B. Tolu
C. Borrazzo
M. Rago
M. Masi
R. El Gawhary
P.C. Gentile
Source :: European Urology. 81:S1412
Publication Year :: 2022
Publisher :: Elsevier BV, 2022.

Tools